In a double-blind, placebo-controlled, phase 3 trial in patients with very-low-risk, low-risk, or intermediate-risk MDS, 93% of the treated patients harbored an SF3B1 mutation [152]. Here, SF3B1 is linked to myelodysplastic syndrome.